Braxia Scientific Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BRAXF research report →
About the company
Braxia Scientific Corp. functions as a medical research entity that also runs clinics, offering ketamine therapies to individuals suffering from depression and linked conditions. Beyond its clinical services, the company is actively engaged in discovering and bringing to market novel pharmaceutical compounds and innovative delivery methods.
- CEO
- Peter Rizakos
- IPO
- 2020
- Employees
- 5
- HQ
- Mississauga, ON, CA
Price Chart
- Market Cap
- $28.33K
- P/E
- -0.09
- P/S
- 0.75
- P/B
- 0.71
- EV/EBITDA
- -0.01
- Div Yield
- 0.00%
- Gross Margin
- 9.12%
- Op Margin
- -397.00%
- Net Margin
- -697.48%
- ROE
- -248.72%
- ROIC
- -408.30%
- Revenue
- $1.88M · 26.70%
- Net Income
- $-13,141,704 · -8.30%
- EPS
- $-0.06 · 16.91%
- Op Income
- $-7,480,135
- FCF YoY
- -82.71%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.44
- Avg Volume
- 314.15K
Get TickerSpark's AI analysis on BRAXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BRAXF coverage
Recent articles, reports, and earnings notes.
No research on BRAXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BRAXF report →Similar companies
Peers in the same neighborhood.